Skip to content

Feasibility and Safety of complete Robotic Assisted complete Da Vinci robotic double-tract reconstruction for proximal gastric cancer

Feasibility and Safety of complete Robotic Assisted complete Da Vinci robotic double-tract reconstruction for proximal gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074457
Enrollment
Unknown
Registered
2023-08-08
Start date
2023-08-08
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

proximal gastric cancer

Interventions

one:Robotic proximal gastrectomy with double-tract reconstruction

Sponsors

Second Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in the study and sign informed consent; (2) Preoperative CT or endoscopic ultrasound confirmed that the lesion was T1 or T2 proximal gastric cancer without lymph node metastasis. All patients did not receive preoperative radiotherapy or chemotherapy, which may affect the outcome. Both male and female, aged =18 years old and = 75 years old; 3. Expected survival time =3 months; 4.ECOG score 0-1; 5. At least one measurable tumor lesion: long diameter =10 mm, short diameter of lymph node =15 mm on spiral CT; The maximum diameter should be =20mm by CT or physical examination. 6. No major organ failure; 7. No severe coagulation dysfunction; 8. Patients who can tolerate electronic gastroscopy.

Exclusion criteria

Exclusion criteria: 1. Intestinal obstruction;2. Extensive adhesion in the peritoneal cavity;3. Obvious inflammation in the abdominal cavity;4. There are high risk factors for poor anastomotic healing, including anastomotic edema, ischemia, obvious tension, severe hypoproteinemia, etc.5. Major organ dysfunction such as heart, kidney, liver and brain;6. Cachexia;7. Severe bleeding and coagulation disorders;8. Patients with severe or uncontrolled cardiovascular and pulmonary diseases, or unstable vital signs due to various reasons;9. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
overall survival;progression free survival;Operation time;Lymph node dissection;R0 resection or not;Gastrointestinal function recovery time;Gastroscope;Tumor markers;Nutrition indicators;Blood routine ;Histopathology;Imaging examination;TNM staging;clinical manifestations;immunological markers;

Secondary

MeasureTime frame
anastomosis time;Intraoperative blood loss;Postoperative hospital stay;Time of drainage tube removal;Infectious indicators;Liver function;Coagulation function;

Countries

China

Contacts

Public ContactHao Chen

Second Hospital of Lanzhou University

ery_chenh@lzu.edu.cn+86 150 0946 7790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026